Decisions 5th July 2016


At the meeting that took place on 5th July, the folllowing decisions were agreed.

 

New Drug Requests

Approved

Evra Contraception Transdermal Patch (TLS Bue)

  • Approved for inclusion onto the formulary for those patients in whom compliance is an issue, TLS Blue

Fosaprepitant (TLS Red)

  • The JFG approved the inclusion of IV fosaprepitant when used in accordance with ASWCS guidelines for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy regimes.

Rituximab (TLS Red)

  • Approved for inclusion onto the formulary as monotherapy for the treatment of RA when patients cannot tolerate DMARDs but rituximab is the most appropriate biologic. 

 

More information required

Ibandronic acid and Zoledronic acid

  • The recent meta-analysis demonstrated that adjuvant bisphosphonates provides benefits in postmenopausal breast cancer patients.  The JFG clinically approved the addition of zoledronate and/or ibandronate for use in this indication however the financial implications for the trusts and CCGs need to be fully considered and agreed before this can be commissioned and added to the formulary.

Other 

Liothyronine

  • The JFG agreed to await the atendence of the applicant at the September meeting before making a final decision.  

Adrenaline autoinjector pen review

  • The JFG discussed a review of the current products available. No decision has been reached as yet for which brand would be considered first line.

Shared Care Protocols/TLS Change in Status

Aripiprazole

  • Updated SCP approved.

  

Typical antipsychotic depots

  • Updated SCP approved.  

  

Rotigotine

  • Updated SCP approved.

Selegeline

  • Updated SCP approved.

  

Ticagrelor

  • Updated SCP approved.  

  

Vortioxetine

  • New SCP approved.

Donepezil

  • New Prescribing guidance approved.

 

Last updated by: on 05-10-2016 12:33